Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 440 participants.

Also called NCT04088513

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 440 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04088513
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04088513. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-22 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)
Acronym
SAST
Condition
G6PD Deficiency
Condition
Stroke
Intervention (Drug)
Aspirin
Intervention (Drug)
Clopidogrel
Lead sponsor
First Affiliated Hospital, Sun Yat-Sen University (class: other)

Record details

Record id
cardio:ct-nct04088513
Content hash
22338a59ab990d434ba6ab44b32a545c54fb99079ce139bcb81bad7ccf74c239